Foundation Medicine Announces Roche Pharmaceuticals (Israel) Ltd. to Commence Commercial Activities in Support of its Molecular Information Products in Oncology

Foundation Medicine, Inc.

today announced that F. Hoffmann La-Roche's affiliate in Israel, Roche Pharmaceuticals (Israel) Ltd., will commence commercial activities in support of its suite of molecular information products. As part of the ex-US collaboration between Foundation Medicine and Roche, Roche Israel will act as the exclusive distributor of Foundation Medicine's current products and services in Israel commencing as of October 24, 2015. The companies will also cooperate on the continued development of Foundation Medicine's groundbreaking molecular information products to drive precision medicine and deliver improved clinical outcomes in cancer. "We are delighted to initiate our ex-US collaboration with Roche Israel and bring a complete suite of molecular information products to the oncology community in Israel," stated David Daly, Chief Commercial Officer of Foundation Medicine. "Roche's strong market presence will be a key differentiator for Foundation Medicine's products, and ultimately will drive increased access to critical molecular information solutions that empower cancer care teams to make informed therapeutic treatment decisions and positively impact clinical outcomes for patients." Roche Israel will commence commercial activities for Foundation Medicine's end-to-end molecular information solutions, including FoundationOne® for solid tumors, FoundationOne® Heme for hematologic malignancies and sarcomas, and FoundationICE®. Avi Danziger, General Manager of Roche Israel stated: "The combination of Foundation Medicine's molecular information suite of products and our expertise in oncology drug development supports our unified quest to tailor the best care and treatment for patients and take a leading position in doing now what patients need next."